Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AEHAW
Aesther Healthcare Acquisition
$0.01
$0.01
$0.06
$0.33
N/AN/A34,287 shs19,500 shs
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
$0.01
-4.8%
$0.01
$0.00
$0.04
N/AN/A97,681 shs9,714 shs
LBPSW
4D pharma
$0.00
$0.04
$1.29
N/AN/A20,931 shsN/A
SRZNW
Surrozen
$0.02
+13.1%
$0.02
$0.01
$0.09
N/AN/A21,338 shs700 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AEHAW
Aesther Healthcare Acquisition
0.00%0.00%-28.57%-56.52%-83.05%
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
-4.76%-8.05%-1.23%+5.26%-12.09%
LBPSW
4D pharma
0.00%0.00%0.00%0.00%0.00%
SRZNW
Surrozen
+20.67%-9.95%-11.27%-28.17%+23.97%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
LBPSW
4D pharma
N/AN/AN/AN/AN/AN/AN/AN/A
SRZNW
Surrozen
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AEHAW
Aesther Healthcare Acquisition
0.00
N/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
0.00
N/AN/AN/A
LBPSW
4D pharma
0.00
N/AN/AN/A
SRZNW
Surrozen
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/A
LBPSW
4D pharma
$522KN/AN/AN/AN/AN/A
SRZNW
Surrozen
$11.64MN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AEHAW
Aesther Healthcare Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/A0.00N/AN/AN/AN/AN/A
LBPSW
4D pharma
N/AN/A0.00N/AN/AN/AN/AN/AN/A
SRZNW
Surrozen
N/AN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/A
LBPSW
4D pharma
N/AN/AN/AN/AN/A
SRZNW
Surrozen
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
AEHAW
Aesther Healthcare Acquisition
N/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/A
LBPSW
4D pharma
N/A
SRZNW
Surrozen
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
AEHAW
Aesther Healthcare Acquisition
2N/AN/ANot Optionable
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
7N/AN/ANot Optionable
LBPSW
4D pharma
N/AN/AN/ANot Optionable
SRZNW
Surrozen
80N/AN/ANot Optionable

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

Media Sentiment Over Time

Aesther Healthcare Acquisition NASDAQ:AEHAW

$0.01 0.00 (0.00%)
As of 06/26/2025

Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.

180 Life Sciences stock logo

180 Life Sciences NASDAQ:ATNFW

$0.0080 0.00 (-4.76%)
As of 06/27/2025 03:55 PM Eastern

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

4D pharma NASDAQ:LBPSW

4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

Surrozen NASDAQ:SRZNW

$0.02 +0.00 (+13.13%)
Closing price 06/27/2025 03:54 PM Eastern
Extended Trading
$0.02 0.00 (-8.29%)
As of 06/27/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.